InterCure Statistics
Total Valuation
InterCure has a market cap or net worth of $37.26 million. The enterprise value is $75.18 million.
Important Dates
The next estimated earnings date is Monday, March 30, 2026, after market close.
| Earnings Date | Mar 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
InterCure has 47.16 million shares outstanding. The number of shares has increased by 8.85% in one year.
| Current Share Class | 54.68M |
| Shares Outstanding | 47.16M |
| Shares Change (YoY) | +8.85% |
| Shares Change (QoQ) | +29.17% |
| Owned by Insiders (%) | 26.05% |
| Owned by Institutions (%) | 2.66% |
| Float | 37.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.52 |
| Forward PS | 0.17 |
| PB Ratio | 0.29 |
| P/TBV Ratio | 0.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.04 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.85, with a Debt / Equity ratio of 0.41.
| Current Ratio | 1.85 |
| Quick Ratio | 1.08 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.41 |
Financial Efficiency
Return on equity (ROE) is -16.68% and return on invested capital (ROIC) is -16.50%.
| Return on Equity (ROE) | -16.68% |
| Return on Assets (ROA) | -7.74% |
| Return on Invested Capital (ROIC) | -16.50% |
| Return on Capital Employed (ROCE) | -16.81% |
| Weighted Average Cost of Capital (WACC) | 7.84% |
| Revenue Per Employee | $225,495 |
| Profits Per Employee | -$65,789 |
| Employee Count | 320 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 1.47 |
Taxes
| Income Tax | -4.90M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.97% in the last 52 weeks. The beta is 0.29, so InterCure's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | -49.97% |
| 50-Day Moving Average | 0.90 |
| 200-Day Moving Average | 1.34 |
| Relative Strength Index (RSI) | 34.93 |
| Average Volume (20 Days) | 54,182 |
Short Selling Information
The latest short interest is 20,573, so 0.04% of the outstanding shares have been sold short.
| Short Interest | 20,573 |
| Short Previous Month | 4,894 |
| Short % of Shares Out | 0.04% |
| Short % of Float | 0.05% |
| Short Ratio (days to cover) | 0.34 |
Income Statement
In the last 12 months, InterCure had revenue of $72.16 million and -$21.05 million in losses. Loss per share was -$0.42.
| Revenue | 72.16M |
| Gross Profit | 12.05M |
| Operating Income | -27.42M |
| Pretax Income | -27.04M |
| Net Income | -21.05M |
| EBITDA | -23.93M |
| EBIT | -27.42M |
| Loss Per Share | -$0.42 |
Full Income StatementBalance Sheet
The company has $15.31 million in cash and $53.23 million in debt, with a net cash position of -$37.92 million or -$0.80 per share.
| Cash & Cash Equivalents | 15.31M |
| Total Debt | 53.23M |
| Net Cash | -37.92M |
| Net Cash Per Share | -$0.80 |
| Equity (Book Value) | 128.29M |
| Book Value Per Share | 2.25 |
| Working Capital | 51.06M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$3.34 million and capital expenditures -$2.16 million, giving a free cash flow of -$5.88 million.
| Operating Cash Flow | -3.34M |
| Capital Expenditures | -2.16M |
| Free Cash Flow | -5.88M |
| FCF Per Share | -$0.12 |
Full Cash Flow StatementMargins
Gross margin is 16.71%, with operating and profit margins of -38.01% and -29.18%.
| Gross Margin | 16.71% |
| Operating Margin | -38.01% |
| Pretax Margin | -37.47% |
| Profit Margin | -29.18% |
| EBITDA Margin | -33.16% |
| EBIT Margin | -38.01% |
| FCF Margin | n/a |
Dividends & Yields
InterCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.85% |
| Shareholder Yield | -8.85% |
| Earnings Yield | -56.50% |
| FCF Yield | -15.79% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
InterCure has an Altman Z-Score of 0.21 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.21 |
| Piotroski F-Score | 2 |
